Madrigal Pharmaceuticals agreed a global licensing partnership with Suzhou Ribo Life Science and Ribocure Pharmaceuticals to acquire six preclinical siRNA programs targeting metabolic dysfunction‑associated steatohepatitis (MASH). The deal includes an upfront payment reported at $60 million and carries potential cumulative milestone payments that could reach roughly $4.4 billion. Madrigal will develop, manufacture and commercialize the programs worldwide while Ribo retains R&D and earlier‑stage capabilities; the agreement expands Madrigal’s MASH pipeline with multi‑mechanistic RNAi assets and underscores continued industry appetite for combination approaches in fatty‑liver therapeutics. Sources: company releases and deal filings.